Pharmaceutical Foreign pharma firms operating in Japan face a recurring dilemma simply stated: Who should be our company president? What makes this decision different from any other country organization? Long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer, in his exclusive column for The Pharma Letter, says that, rather than hiding behind the knee jerk answer that says, “Because Japan is different,” let’s take an objective look at the issues. 16 September 2019